Eli Lilly has made some massive breakthroughs in pharmaceutical technology, but will it translate to money for investors? Read our forecast and find out.

Eli Lilly (LLY) has bought the pain therapy developer 4E Therapeutics, the Austin-based neuroscience company announced on Tuesday, marking the weight loss drugmaker’s latest acquisition. 4E is a ...

Swedish biotech AlzeCure Pharma announced on Tuesday a collaboration and a licensing agreement with Eli Lilly (LLY) to develop an Alzheimer’s therapy as part of a deal that could potentially exceed ...

Eli Lilly and Company (NYSE:LLY) rose around 12% in May 2026, primarily driven by strong FQ1 2026 earnings beat and FDA approval for Foundayo and expansion of insurance coverage of obesity treatment.

Retatrutide's 19% weight loss data pushed LLY to a 52-week high, and four straight EPS beats make the $1,500 optimistic target achievable. AZN's elecoglipron delivered only 12% weight loss in Phase 3 ...

Looking ahead to 2030, our model projects LLY could trade at an average price of $1,621.02, with a potential range between $1,215.76 and $2,026.27. This represents a potential 33.5% return from ...

Federal agents were looking for records that might shed light on why chemicals overheated, threatening a catastrophe in Orange County. By Tim Arango and Livia Albeck-Ripka Livia Albeck-Ripka reported ...

A trailer loaded with fireworks erupted in flames along a Tennessee interstate Saturday night, sending pyrotechnics shooting across the roadway and forcing authorities to temporarily shut down traffic ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.1% in the afternoon session after the company reported positive Phase 3 data for retatrutide, its next-generation triple-agonist ...

Blue Origin is one of two companies — Elon Musk’s SpaceX is the other — that NASA has hired to take astronauts from lunar orbit to the moon’s surface. The plan for Blue Origin’s Blue Moon lander ...